Clinical Trial

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-09-14; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2024-03-11
Trial Details
NCT Number NCT06046248
Lead Sponsor Northside Hospital, Inc.
Collaborators: Sanofi
Conditions Chronic Graft Versus Host Disease
Enrollment 25 participants
Start Date 2024-01-29
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-20